Presentation is loading. Please wait.

Presentation is loading. Please wait.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis  Mary P. McGowan, MD, FNLA 

Published byPavlína Dostálová Modified over 5 years ago

Similar presentations

Presentation on theme: "Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis  Mary P. McGowan, MD, FNLA "— Presentation transcript:

1 Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis  Mary P. McGowan, MD, FNLA  Journal of Clinical Lipidology  Volume 7, Issue 3, Pages S21-S26 (May 2013) DOI: /j.jacl Copyright © 2013 National Lipid Association Terms and Conditions

2 Figure 1 Time–course effect of LDL-apheresis on lipid levels. A, immediately after apheresis; B, immediately before apheresis; TC, total cholesterol. © Copyright Kaneka Pharma America, LLC This figure was reprinted with permission from Kaneka Pharma America, LLC. A, immediatley after apheresis; B, immediately before apheresis; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); TC, total cholesterol. Journal of Clinical Lipidology 2013 7, S21-S26DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions

3 Figure 2 Liposorber system.
© Copyright Kaneka Pharma America, LLC This figure was reprinted with permission from Kaneka Pharma America, LLC. Journal of Clinical Lipidology 2013 7, S21-S26DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions

4 Figure 3 Diagram of the HELP system. LDL, low-density lipoprotein.
Journal of Clinical Lipidology 2013 7, S21-S26DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions

5 Figure 4 Kaplan-Meier curves for the proportion of patients without coronary events receiving LDL-apheresis in combination with lipid-lowering medications or medications alone. Reprinted with permission from Mabuchi et al.23 LDL, low-density lipoprotein. Journal of Clinical Lipidology 2013 7, S21-S26DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions

Download ppt "Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis  Mary P. McGowan, MD, FNLA "

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Cognitive Safety Task Force: 2014 update
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
An assessment by the Statin Diabetes Safety Task Force: 2014 update

An assessment by the Statin Diabetes Safety Task Force: 2014 update
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Jari A. Laukkanen, MD, PhD, Tanjaniina Laukkanen, MSc, Setor K

Jari A. Laukkanen, MD, PhD, Tanjaniina Laukkanen, MSc, Setor K
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

Similar presentations

Ads by Google